Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions rather than a financial performance report.
Material Changes
The material change reported is the vesting of share options for Dr. M. M. Slaoui, a Person Discharging Managerial Responsibility. The three-year performance period for a 2008 award under the GlaxoSmithKline Share Option Plan ended on December 31, 2010, making the entire grant exercisable.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investors
- Transaction Type: Vesting of American Depositary Shares (ADSs) for a connected person of Dr. M. M. Slaoui.
- Shares Vested: 1,100 ADSs.
- Option Details: Original grant made in 2008 with an option price of US$44.75.
- Notification Date: The company and the connected person were advised of the transaction on February 22, 2011.
- Reporting Date: February 23, 2011.